

# Yi Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/140616/publications.pdf>

Version: 2024-02-01

155  
papers

21,690  
citations

34016

52  
h-index

10127

140  
g-index

157  
all docs

157  
docs citations

157  
times ranked

19014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciltacabtagene Autoleucl, an Anti-CD19 B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	0.8	160
2	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.4	13
3	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	3.3	43
4	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.2	27
5	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	2.0	5
6	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.3	27
7	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
8	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 3708-3721.	0.6	53
9	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucl: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	0.6	4
10	Axicabtagene ciloleucl as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	15.2	114
11	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	1.0	39
12	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
13	Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
14	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 171-187.	1.3	9
15	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	6.9	17
16	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
17	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
18	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucl. <i>Blood</i> , 2021, 137, 1832-1835.	0.6	48

#	ARTICLE	IF	CITATIONS
19	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
20	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
21	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021, 5, 1029-1036.	2.5	9
22	Transiently structured head domains control intermediate filament assembly. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	32
23	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
24	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
25	Impact of hypoalbuminemia on the prognosis of relapsed/refractory Bâ€cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	1.1	3
26	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
27	Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. <i>Kidney International Reports</i> , 2021, 6, 1416-1422.	0.4	17
28	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
29	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 116.	2.8	44
30	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
31	Lines of therapy before autologous stem cell transplant and <sc>CARâ€T</sc> affect outcomes in aggressive <sc>Nonâ€Hodgkin's</sc> lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	2.0	4
32	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	2.5	13
33	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large Bâ€cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	1.2	88
34	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood Cancer Journal</i> , 2021, 11, 124.	2.8	9
35	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	0.8	12
36	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021, 398, 314-324.	6.3	711

#	ARTICLE	IF	CITATIONS
37	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <scp>T</scp> cell therapy. American Journal of Hematology, 2021, 96, E399-E402.	2.0	14
38	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, The, 2021, 398, 491-502.	6.3	315
39	Outcomes in primary cutaneous diffuse large B cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	0.8	8
40	Phase separation in RNA biology. Journal of Genetics and Genomics, 2021, 48, 872-880.	1.7	14
41	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	2.5	42
42	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large <scp>B</scp> cell lymphoma patients treated with axicabtagene ciloleucl. American Journal of Hematology, 2021, 96, E427-E430.	2.0	7
43	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	2.0	8
44	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	2.0	6
45	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	1.4	25
46	Enhancing the Rã€SS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	2.0	37
47	Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia, 2020, 34, 1383-1393.	3.3	17
48	Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenstrã€m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
49	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	3.3	29
50	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	3.2	32
51	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucl in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	2.5	238
52	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	2.8	3
53	Predictors of short-term survival in Waldenstrã€m Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	0.6	2
54	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27

#	ARTICLE	IF	CITATIONS
55	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
56	Redox-mediated regulation of an evolutionarily conserved cross- $\beta$ structure formed by the TDP43 low complexity domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28727-28734.	3.3	44
57	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	0.8	481
58	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
59	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
60	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncotimmunology</i> , 2020, 9, 1744947.	2.1	26
61	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020, 58, 58-64.	1.0	31
62	Immunotherapy of lymphomas. <i>Journal of Clinical Investigation</i> , 2020, 130, 1576-1585.	3.9	32
63	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
64	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
65	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
66	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
67	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	13.9	1,130
68	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
69	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
70	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
71	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
72	Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2361-2364.	1.4	12

#	ARTICLE	IF	CITATIONS
73	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€“2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
74	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
75	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	3.3	8
76	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
77	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
78	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
79	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	12.5	114
80	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
81	<i>MYD88</i> mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
82	Chimeric antigen receptor T-cell therapy â€” assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
83	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64
84	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
85	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	2.8	18
86	Serum free light chain measurements to reduce 24â€“h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3
87	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006588.	1.3	51
88	Predictors of symptomatic hyperviscosity in WaldenstrÃ¶m macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
89	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
90	Toxic PR <sub>n</sub> poly-dipeptides encoded by the <i>C9orf72</i> repeat expansion block nuclear import and export. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E1111-E1117.	3.3	202

#	ARTICLE	IF	CITATIONS
91	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
92	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
93	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	0.6	50
94	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
95	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	0.6	335
96	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	2.7	15
97	Cross- $\beta$ polymerization and hydrogel formation by low-complexity sequence proteins. <i>Methods</i> , 2017, 126, 3-11.	1.9	19
98	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
99	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
100	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
101	Structure of FUS Protein Fibrils and Its Relevance to Self-Assembly and Phase Separation of Low-Complexity Domains. <i>Cell</i> , 2017, 171, 615-627.e16.	13.5	605
102	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. <i>Cytotherapy</i> , 2017, 19, 1426-1437.	0.3	9
103	Elevation of serum lactate dehydrogenase in <sc>AL</sc> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
104	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
105	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
106	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
107	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
108	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49

#	ARTICLE	IF	CITATIONS
109	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes are elevated in pancreatic cancer and are primed by tumor-derived exosomes. <i>Onc Immunology</i> , 2017, 6, e1252013.	2.1	59
110	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
111	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
112	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 101-108.	0.5	9
113	Induction therapy preautologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
114	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
115	Pulmonary Valve Replacement With Balloon-Expandable Prosthesis Under Direct Vision: A Novel Therapeutic Approach. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1576-1577.	0.7	1
116	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
117	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
118	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
119	N-terminal fragment of the type B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
120	Cell Damage in Light Chain Amyloidosis. <i>Journal of Biological Chemistry</i> , 2016, 291, 19813-19825.	1.6	58
121	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	15.2	133
122	Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. <i>Cell</i> , 2016, 167, 789-802.e12.	13.5	363
123	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30
124	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. <i>American Journal of Roentgenology</i> , 2016, 206, 655-659.	1.0	54
125	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
126	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18



#	ARTICLE	IF	CITATIONS
127	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans. PLoS ONE, 2015, 10, e0121546.	1.1	100
128	Intratumoral CD14+ Cells and Circulating CD14+HLA-DR <sup>lo</sup> /neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 4224-4233.	3.2	33
129	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	2.0	76
130	Immune independent crosstalk between lymphoma and myeloid suppressor CD14 <sup>+</sup> HLA-DR <sup>low</sup> /neg <sup>+</sup> monocytes mediates chemotherapy resistance. Oncolmmunology, 2015, 4, e996470.	2.1	10
131	The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei. Cell, 2015, 163, 829-839.	13.5	262
132	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B <sup>+</sup> and T <sup>+</sup> cell non-Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 1116-1120.	2.0	16
133	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology, 2014, 89, 302-305.	2.0	4
134	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	2.0	32
135	Strategies for improving the reporting of human immunophenotypes by flow cytometry. , 2014, 2, 18.		11
136	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DR <sup>lo</sup> /neg Cells): The Gateway to Improved Responses. Frontiers in Immunology, 2014, 5, 147.	2.2	55
137	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50
138	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2013, 88, 375-378.	2.0	34
139	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	1.4	440
140	Disseminated Histoplasmosis: A Cause of Hemophagocytic Syndrome. Mayo Clinic Proceedings, 2013, 88, e123.	1.4	4
141	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	0.8	193
142	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	0.8	147
143	Outcomes of patients with POEMS syndrome treated initially with radiation. Blood, 2013, 122, 68-73.	0.6	74
144	The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1021-1022.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Association of an increased frequency of CD14 <sup>+</sup> HLA-DR <sup>lo</sup> /neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). <i>British Journal of Haematology</i> , 2012, 156, 674-676.	1.2	58
146	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>low</sup> monocytes in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 872-881.	0.6	218
147	Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. <i>Advances in Hematology</i> , 2011, 2011, 1-17.	0.6	59
148	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>low</sup> monocytes in prostate cancer. <i>Prostate</i> , 2010, 70, 443-455.	1.2	233
149	Systemic immune suppression in glioblastoma: the interplay between CD14 <sup>+</sup> HLA-DR <sup>lo</sup> /neg monocytes, tumor factors, and dexamethasone. <i>Neuro-Oncology</i> , 2010, 12, 631-644.	0.6	194
150	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. <i>Neuro-Oncology</i> , 2010, 12, 351-365.	0.6	197
151	Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. <i>Clinical Cancer Research</i> , 2009, 15, 7246-7255.	3.2	176
152	68-Year-Old Man With Fatigue, Fever, and Weight Loss. <i>Mayo Clinic Proceedings</i> , 2005, 80, 939-942.	1.4	2
153	Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. <i>Blood</i> , 2002, 99, 457-462.	0.6	162
154	Origins of circulating endothelial cells and endothelial outgrowth from blood. <i>Journal of Clinical Investigation</i> , 2000, 105, 71-77.	3.9	1,370
155	Circulating Activated Endothelial Cells in Sickle Cell Anemia. <i>New England Journal of Medicine</i> , 1997, 337, 1584-1590.	13.9	593